Abbott to acquire Cephea Valve Technologies, Inc.
Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015. (Source: World Pharma News)
Source: World Pharma News - January 16, 2019 Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news

Sleeping less than six hours a night may increase cardiovascular risk
People who sleep less than six hours a night may be at increased risk of cardiovascular disease compared with those who sleep between seven and eight hours, suggests a new study published in the Journal of the American College of Cardiology. Poor quality sleep increases the risk of atherosclerosis - plaque buildup in the arteries throughout the body - according to the study. (Source: World Pharma News)
Source: World Pharma News - January 16, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
Bristol-Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC). (Source: World Pharma News)
Source: World Pharma News - January 15, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Muscle stem cells can drive cancer that arises in Duchenne muscular dystrophy
People with Duchenne muscular dystrophy (DMD) can develop an otherwise-rare muscle cancer, called rhabdomyosarcoma, due to the muscle cells' continuous work to rebuild the damaged tissue. However, little is known about how the cancer arises, hindering development of a treatment or test that could predict cancer risk. (Source: World Pharma News)
Source: World Pharma News - January 15, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

SMi presents the 2nd Annual Conference: Injectable Drug Delivery 2019
15 - 16 May 2019, London, UK. The global injectable drug delivery market is expected to grow from $400 billion to $1200 billion by 2046 with a CAGR of 12.8%. Injectable drug delivery is a method of drug administration into the body with a needle via various routes including intramuscular and intravenous. (Source: World Pharma News)
Source: World Pharma News - January 14, 2019 Category: Pharmaceuticals Tags: Featured Events Source Type: news

US FDA accepts regulatory submissions for review of tafamidis to treat transthyretin amyloid cardiomyopathy
Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer has submitted two NDAs based on two forms of tafamidis: meglumine salt and free acid. (Source: World Pharma News)
Source: World Pharma News - January 14, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Danish malaria vaccine passes test in humans
For many years, a team of researchers at the University of Copenhagen have been focussing on developing a vaccine that can protect against the disease pregnancy malaria from which 220,000 people die every year. Now they have come a significant step closer to being able to introduce such a vaccine in the market. In a new study published in the scientific journal Clinical Infectious Diseases the vaccine has been subjected to so-called phase one clinical trial, and the results are uplifting: (Source: World Pharma News)
Source: World Pharma News - January 11, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

EVENITY ™ (romosozumab) receives approval in Japan for the treatment of osteoporosis in patients at high risk of fracture
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.(1) Amgen and UCB are co-developing EVENITY worldwide, with development in Japan being led by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., headquartered in Tokyo. (Source: World Pharma News)
Source: World Pharma News - January 10, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Stem cell study offers clues for optimizing bone marrow transplants and more
Bone marrow transplants, which involve transplanting healthy blood stem cells, offer the best treatment for many types of cancers, blood disorders and immune diseases. Even though 22,000 of these procedures are performed each year in the US, much remains to be understood about how they work. (Source: World Pharma News)
Source: World Pharma News - January 9, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Boehringer Ingelheim initiates a collaborative partnership with Science 37 to accelerate patient centricity in the development of novel therapies
Science 37, an industry leader in virtual clinical trials, and Boehringer Ingelheim announced a technology enterprise collaboration agreement that will support Boehringer Ingelheim in running remote clinical trials. Science 37 is licensing access to its proprietary software platform, NORA® (Network Oriented Research Assistant), which leverages mobile technology and telemedicine capabilities, enabling patients to (Source: World Pharma News)
Source: World Pharma News - January 8, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Researchers uncover new mechanism of gene regulation involved in tumor progression
Genes contain all the information needed for the functioning of cells, tissues, and organs in our body. Gene expression, meaning when and how are the genes being read and executed, is thoroughly regulated like an assembly line with several things happening one after another. (Source: World Pharma News)
Source: World Pharma News - January 8, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Sandoz and Pear Therapeutics announce US launch of reSET-OTM to help treat Opioid Use Disorder
Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD). reSET-O*, cleared by the US Food and Drug Administration (FDA) in December, is immediately available. (Source: World Pharma News)
Source: World Pharma News - January 7, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

AstraZeneca announces organisational changes
AstraZeneca is today announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a new phase in its strategic development. Included in the changes will be the arrival at AstraZeneca of the world-renowned oncology scientist, José Baselga, as well as the creation of: (Source: World Pharma News)
Source: World Pharma News - January 7, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Pfizer initiates phase 2b/3 clinical trial for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with moderate to severe alopecia areata
Pfizer Inc. (NYSE: PFE) announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body, and currently has no approved therapies. (Source: World Pharma News)
Source: World Pharma News - January 5, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Stopping cancer from recruiting immune system double agents
Cancerous tumors trick myeloid cells, an important part of the immune system, into perceiving them as a damaged part of the body; the tumors actually put myeloid cells to work helping them grow and metastasize (spread). A research team co-led by scientists at Rush University Medical Center have discovered a potential therapy that can disrupt this recruitment and abnormal function of myeloid cells in laboratory mice. (Source: World Pharma News)
Source: World Pharma News - January 4, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bristol-Myers Squibb to acquire Celgene to create a premier innovative biopharma company
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. (Source: World Pharma News)
Source: World Pharma News - January 3, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Tumors backfire on chemotherapy
Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of the tumor to facilitate breast-conserving surgery, and can even eradicate the tumor, leaving few or no cancerous cells for the surgeon to remove. In those cases, the patients are very likely to remain cancer-free for life after surgery. (Source: World Pharma News)
Source: World Pharma News - January 2, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Top 20 breaking World Pharma News of 2018
World Pharma News proudly presents the top 20 most popular breaking news from 2018. Have a wonderful 2019 New(s) Year filled with health, happiness, and spectacular success! (Source: World Pharma News)
Source: World Pharma News - January 1, 2019 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Pediatric leukemia 'super drug' could be developed in the coming years
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development. When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. (Source: World Pharma News)
Source: World Pharma News - December 28, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, controlled, Phase III SOLO-3 trial of Lynparza (olaparib) tablets in 266 patients with relapsed ovarian cancer after two or more lines of treatment. (Source: World Pharma News)
Source: World Pharma News - December 27, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Pediatric leukemia 'super drug' could be developed in the coming years
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development. When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. (Source: World Pharma News)
Source: World Pharma News - December 26, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first treatment for rare blood disease
The U.S. Food and Drug Administration today approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older. (Source: World Pharma News)
Source: World Pharma News - December 21, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Merck assigns Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon
Merck, a leading science and technology company, today announced it has evolved its agreement with Intrexon Corporation (NASDAQ: XON) for the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. (Source: World Pharma News)
Source: World Pharma News - December 20, 2018 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Anticancer vaccines gain new lease of life with personalisation techniques
Anticancer vaccines have gained a new lease of life with techniques to personalise them to individual patients. Cutting edge developments in this re-energised field were revealed at the ESMO Immuno-Oncology Congress in Geneva, Switzerland. The original anticancer vaccines, launched in the late 1990s, were based on shared tumour antigens and failed to induce a potent immune response. (Source: World Pharma News)
Source: World Pharma News - December 19, 2018 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Amgen Golden Tickets provide startup companies with free lab space to further advance innovative science and technology
Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics and PanTher Therapeutics have each won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge, Mass. facility on Dec. 11, 2018. (Source: World Pharma News)
Source: World Pharma News - December 18, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Sutimlimab shows promise for hard-to-treat, rare blood disorder
In a first-in-human clinical trial reported today in Blood, the investigational drug sutimlimab appeared to be effective in treating cold agglutinin disease, a rare chronic blood disorder for which there are currently no approved treatments. Cold agglutinin disease is caused by a malfunction in the immune system that causes antibodies - components of the immune system that are produced in the blood and help the body fight off disease - to mistakenly latch onto and kill red blood cells. (Source: World Pharma News)
Source: World Pharma News - December 17, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance
Bristol-Myers Squibb Company (NYSE:BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients treated with standard-of-care checkpoint inhibitors. (Source: World Pharma News)
Source: World Pharma News - December 17, 2018 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV ™ (bevacizumab)
Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin (bevacizumab). (Source: World Pharma News)
Source: World Pharma News - December 14, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

First line immunotherapy combination fails to improve overall survival in lung cancer
First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress.(1) The combination of immune checkpoint inhibitors and chemotherapy has been successfully tested in different trials as first line therapy for (Source: World Pharma News)
Source: World Pharma News - December 13, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis receives European Commission approval for self-administration of Xolair ® across all indications
Novartis today announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment. With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU. (Source: World Pharma News)
Source: World Pharma News - December 13, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Helping the anti-parasitic medicine go down
Scientists have developed a new way to deliver anti-parasitic medicines more efficiently. An international team, led by Professor Francisco Goycoolea from the University of Leeds and Dr Claudio Salomon from the Universidad Nacional de Rosario, Argentina, and in collaboration with colleagues at the University of Münster, Germany, have developed a novel pharmaceutical formulation to administer triclabendazole - an anti-parasitic drug used to treat a type of flatworm infection - in billions of tiny capsules. (Source: World Pharma News)
Source: World Pharma News - December 12, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Scientists pave the way for saliva test for Alzheimer's disease
University of Alberta scientists have identified three biomarkers for detecting mild cognitive impairment and Alzheimer's disease in saliva samples. The research has promising results for application in a clinical setting. The research team combines expertise in metabolomics from Liang Li, professor in the Department of Chemistry, and neurodegenerative disorders from Roger Dixon, professor in the Department of Psychology. (Source: World Pharma News)
Source: World Pharma News - December 12, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Amgen contributes $2 million to groundbreaking program providing cancer patients of all backgrounds access to U.S. clinical trials
Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, have teamed up to support more equitable access to clinical trials for cancer patients in the U.S. Through a corporate donation, Amgen has contributed $2 million to Lazarex's IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, (Source: World Pharma News)
Source: World Pharma News - December 11, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Drug cocktail turns off the juice to cancer cells
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth - this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, recently published in Cell Reports, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply. (Source: World Pharma News)
Source: World Pharma News - December 11, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs
Today, the U.S. Food and Drug Administration cleared a mobile medical application (app) to help increase retention (the amount of time a patient participates) in an outpatient treatment program for individuals with opioid use disorder (OUD). The reSET-O app is a prescription cognitive behavioral therapy intended to be used in addition to outpatient treatment under the care of a health care professional, (Source: World Pharma News)
Source: World Pharma News - December 10, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines
AstraZeneca today announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines. The Functional Genomics Centre will further develop CRISPR technology to better understand the biology of cancer, (Source: World Pharma News)
Source: World Pharma News - December 10, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

MIT engineers repurpose wasp venom as an antibiotic drug
The venom of insects such as wasps and bees is full of compounds that can kill bacteria. Unfortunately, many of these compounds are also toxic for humans, making it impossible to use them as antibiotic drugs. After performing a systematic study of the antimicrobial properties of a toxin normally found in a South American wasp, researchers at MIT have now created variants of the peptide that are potent against bacteria but nontoxic to human cells. (Source: World Pharma News)
Source: World Pharma News - December 7, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: World Pharma News)
Source: World Pharma News - December 6, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Statins overprescribed for primary prevention
Even healthy people who don't suffer from a cardiovascular disease are prescribed cholesterol-lowering drugs, known as statins, if they meet certain risk criteria. However, for years the use of statins for primary prevention has been hotly debated among experts. "Ultimately, this measure helps to prevent heart attacks or strokes in only a few cases. But all people who take statins are at risk of experiencing the side effects," says Milo Puhan, professor of epidemiology and public health at the University of Zurich. (Source: World Pharma News)
Source: World Pharma News - December 6, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). (Source: World Pharma News)
Source: World Pharma News - December 5, 2018 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Cannabis-based compound may reduce seizures in children with epilepsy
Interest has been growing in the use of cannabinoids - the active chemicals in cannabis or marijuana - for the treatment of epilepsy in children. A recent Epilepsia analysis of relevant published studies indicates that this strategy looks promising. The analysis included four randomized controlled trials and 19 non-randomized studies, primarily involving cannabidiol, a particular type of cannabinoid that does not have psychoactive effects. (Source: World Pharma News)
Source: World Pharma News - December 5, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer reaches a global agreement with AbbVie
Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer's proposed adalimumab biosimilar for many countries around the world. (Source: World Pharma News)
Source: World Pharma News - December 4, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

New Parkinson's disease drug target revealed through study of fatty acids
The human brain is rich in lipids. Investigators studying Parkinson's disease (PD) have become increasingly interested in lipids since both molecular and genetic studies have pointed to the disruption of the balance of the brain's lipids as a potentially critical contributor to this disease. Beginning in yeast and moving through various model organisms and human cells, a new study led by investigators from (Source: World Pharma News)
Source: World Pharma News - December 4, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition, which Bayer is currently developing jointly with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA). (Source: World Pharma News)
Source: World Pharma News - December 3, 2018 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma
In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). They found that 52 percent of those patients responded favorably to the therapy. Forty percent had a complete response and 12 percent had a partial response. (Source: World Pharma News)
Source: World Pharma News - December 3, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS. (Source: World Pharma News)
Source: World Pharma News - November 30, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

When good macrophages go bad
Many factors affect cancer treatment outcome, such as the size and location of the tumor, availability of effective treatments, and timing of intervention. But some cancers are so aggressive that outcome is poor, even after early diagnosis and chemotherapy. Researchers have focused their attention on trying to understand what makes some cancers less treatable than others. (Source: World Pharma News)
Source: World Pharma News - November 29, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Sanofi builds focus on rare blood disorders and cancers
Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research as scientists look for new treatments for serious and life-threatening conditions. To help meet this need, Sanofi has significantly increased its focus on hematology, making a number of important investments to advance (Source: World Pharma News)
Source: World Pharma News - November 29, 2018 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

91 percent response rate for venetoclax against newly diagnosed AML in older adults
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. (Source: World Pharma News)
Source: World Pharma News - November 28, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion
The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of adult and pediatric patients with solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation that are either metastatic or where surgical resection will likely result in severe morbidity, and (Source: World Pharma News)
Source: World Pharma News - November 28, 2018 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news